Feasibility of Telerehabilitation in HIV-patients
Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients
The aim of this study is to assess the feasibility and the effects of a 6-week telerehabilitation on the three domains of the International Classification of Functioning, Disability and Health in HIV-infected patients under highly active antiretroviral therapy (HAART).
HIV-infected patients were randomized either into an Endurance and Resistance Training Exercise (ERTE) group or a control (CON) group. Telerehabilitation was realized in a public fitness center, with online guidance and weekly telephone advice, 3 times per week for 6 weeks. Feasibility was determined by recruitment rate, retention rate and adverse events. Secondary outcomes were impact on body composition, inflammation and coagulation (C-reactive protein, D-dimer), physical fitness and quality of life (WHOQOL-HIV).
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 years or older
- under HAART treatment
- native French speaker
Exclusion Criteria:
- AIDS diagnosis
- physical and/or psychiatric impairments that seriously impaired physical activity
- pregnant
- Unstable (defined by any modification of health outcomes during the last 6 months).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
介入なし:対照群
普段のお手入れ
|
|
実験的:Endurance and Resistance Training Exercise
|
Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Recruitment rate
時間枠:At study completion (after 6 weeks)
|
Number of eligible participants who enrolled in the program out of the number were recruited
|
At study completion (after 6 weeks)
|
Retention rate
時間枠:At study completion (after 6 weeks)
|
Percentage of patients lost to follow-up
|
At study completion (after 6 weeks)
|
Adverse events
時間枠:At study completion (after 6 weeks)
|
Percentage of patients who experienced one or more adverse events
|
At study completion (after 6 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Weight
時間枠:Assessments at baseline and at 6 weeks
|
Weight (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
Lean body mass
時間枠:Assessments at baseline and at 6 weeks
|
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
Fat body mass
時間枠:Assessments at baseline and at 6 weeks
|
Lean body mass (kg) is measured by using a bioelectrical impedance analysis
|
Assessments at baseline and at 6 weeks
|
C-reactive protein
時間枠:Assessments at baseline and at 12 weeks
|
C-reactive protein is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
D-dimer
時間枠:Assessments at baseline and at 12 weeks
|
D-dimer is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
CD4+ T cell counts
時間枠:Assessments at baseline and at 12 weeks
|
CD4+ T cell counts is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
Viral load
時間枠:Assessments at baseline and at 12 weeks
|
Viral load is measured by a blood test
|
Assessments at baseline and at 12 weeks
|
Functional exercise capacity
時間枠:Assessments at baseline and at 6 weeks
|
Functional exercise capacity is measured by a 6-minute walk test
|
Assessments at baseline and at 6 weeks
|
Flexibility
時間枠:Assessments at baseline and at 6 weeks
|
Flexibility is measured by Toe touch test and sit and reach test
|
Assessments at baseline and at 6 weeks
|
Lower body muscular strength
時間枠:Assessments at baseline and at 6 weeks
|
Lower body muscular strength is measured by 30-s chair-stand test
|
Assessments at baseline and at 6 weeks
|
Upper limb strength
時間枠:Assessments at baseline and at 6 weeks
|
Upper limb strength is measured by hand grip strength tool
|
Assessments at baseline and at 6 weeks
|
Quality of life
時間枠:Assessments at baseline and at 6 weeks
|
Quality of life is measured by World Health Organization Quality of Life HIV Instrument
|
Assessments at baseline and at 6 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Telerehabilitation HIV
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。